JP2020526514A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526514A5
JP2020526514A5 JP2020500131A JP2020500131A JP2020526514A5 JP 2020526514 A5 JP2020526514 A5 JP 2020526514A5 JP 2020500131 A JP2020500131 A JP 2020500131A JP 2020500131 A JP2020500131 A JP 2020500131A JP 2020526514 A5 JP2020526514 A5 JP 2020526514A5
Authority
JP
Japan
Prior art keywords
immunosuppressant
composition
use according
months
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020500131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/040957 external-priority patent/WO2019010335A1/en
Publication of JP2020526514A publication Critical patent/JP2020526514A/ja
Publication of JP2020526514A5 publication Critical patent/JP2020526514A5/ja
Priority to JP2023108011A priority Critical patent/JP7670759B2/ja
Pending legal-status Critical Current

Links

JP2020500131A 2017-07-06 2018-07-05 ムコ多糖症ｉ型を治療するための遺伝子治療 Pending JP2020526514A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023108011A JP7670759B2 (ja) 2017-07-06 2023-06-30 ムコ多糖症ｉ型を治療するための遺伝子治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762529385P 2017-07-06 2017-07-06
US62/529,385 2017-07-06
US201762530614P 2017-07-10 2017-07-10
US62/530,614 2017-07-10
US201862616106P 2018-01-11 2018-01-11
US62/616,106 2018-01-11
PCT/US2018/040957 WO2019010335A1 (en) 2017-07-06 2018-07-05 AAV9 MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023108011A Division JP7670759B2 (ja) 2017-07-06 2023-06-30 ムコ多糖症ｉ型を治療するための遺伝子治療

Publications (2)

Publication Number Publication Date
JP2020526514A JP2020526514A (ja) 2020-08-31
JP2020526514A5 true JP2020526514A5 (cg-RX-API-DMAC7.html) 2021-08-12

Family

ID=63036365

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500131A Pending JP2020526514A (ja) 2017-07-06 2018-07-05 ムコ多糖症ｉ型を治療するための遺伝子治療
JP2023108011A Active JP7670759B2 (ja) 2017-07-06 2023-06-30 ムコ多糖症ｉ型を治療するための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023108011A Active JP7670759B2 (ja) 2017-07-06 2023-06-30 ムコ多糖症ｉ型を治療するための遺伝子治療

Country Status (11)

Country Link
US (2) US11890329B2 (cg-RX-API-DMAC7.html)
EP (1) EP3676385A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020526514A (cg-RX-API-DMAC7.html)
KR (2) KR20240063170A (cg-RX-API-DMAC7.html)
AU (1) AU2018298133A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000063A2 (cg-RX-API-DMAC7.html)
CA (1) CA3068328A1 (cg-RX-API-DMAC7.html)
IL (1) IL271780A (cg-RX-API-DMAC7.html)
MA (1) MA50016A (cg-RX-API-DMAC7.html)
SG (1) SG11201912631PA (cg-RX-API-DMAC7.html)
WO (1) WO2019010335A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014235096B2 (en) 2013-03-15 2020-03-19 The Trustees Of The University Of Pennsylvania Compositions and methods for treating MPSI
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
CA3012195A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
KR102883778B1 (ko) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
CN120860258A (zh) * 2018-11-30 2025-10-31 北京诺华制药有限公司 Aav病毒载体及其用途
WO2021081217A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
KR20220131522A (ko) * 2020-01-22 2022-09-28 리젠엑스바이오 인크. 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
AU2021325891A1 (en) * 2020-08-10 2023-04-06 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders
JP2023537903A (ja) * 2020-08-10 2023-09-06 プリベイル セラピューティクス，インコーポレーテッド リソソーム障害に対する遺伝子療法
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022170082A1 (en) * 2021-02-05 2022-08-11 Regents Of The University Of Minnesota Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
EP4294461A4 (en) * 2021-02-22 2025-06-25 Decibel Therapeutics, Inc. METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR
WO2024205528A1 (en) * 2023-03-31 2024-10-03 Erci̇yes Üni̇versi̇tesi̇ Strateji̇ Geli̇şti̇rme Dai̇re Başkanliği A multi-head for use in electrohydrodynamic

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
CA2099503C (en) 1991-11-14 2007-10-09 Hamish Steele Scott Synthetic alpha-l-iduronidase and genetic sequences encoding same
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
AU4072499A (en) 1998-05-13 1999-11-29 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
CA2412882A1 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7155804B2 (en) 2003-09-17 2007-01-02 Moog Inc. Method of forming an electric motor
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20090062144A1 (en) 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
BR112012010755A2 (pt) 2009-11-05 2015-09-22 Proyecto Biomedicina Cima Sl constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP3196301B1 (en) 2012-07-11 2018-10-17 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of monogenic diseases
WO2014125647A1 (ja) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 光受信装置
AU2014235096B2 (en) 2013-03-15 2020-03-19 The Trustees Of The University Of Pennsylvania Compositions and methods for treating MPSI
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP6479777B2 (ja) 2013-06-11 2019-03-06 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
AU2015320694B2 (en) 2014-09-24 2021-11-11 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
EP3204503A1 (en) * 2014-10-06 2017-08-16 Arthrogen BV Aav-based gene therapy
HK1256341A1 (zh) * 2015-05-15 2019-09-20 明尼苏达大学董事会 用於治疗性递送到中枢神经系统的腺相关物
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
TWI617573B (zh) 2015-08-06 2018-03-11 中央研究院 用於酵素置換療法的改造酵素
US20170059692A1 (en) * 2015-08-28 2017-03-02 Laufer Wind Group Llc Mitigation of Small Unmanned Aircraft Systems Threats
CA2995733A1 (en) * 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Aav-epo for treating companion animals
KR102738860B1 (ko) 2015-10-23 2024-12-04 유니버시티 오브 아이오와 리써치 파운데이션 리소좀 축적 질환 (lsd)을 갖는 포유동물의 치료 방법에 사용하기 위한 aav 입자를 포함하는 약제학적 조성물
ES2934848T3 (es) 2015-12-11 2023-02-27 Univ Pennsylvania Método de purificación escalable para AAV8
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
WO2017123757A1 (en) * 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
CA3012195A1 (en) * 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
JP2020500928A (ja) 2016-11-15 2020-01-16 リジェネクスバイオ インコーポレイテッド Ｍｐｓｉおよびｍｐｓｉｉならびに他の神経障害において神経機能を改善するための方法
KR20250022877A (ko) 2017-01-31 2025-02-17 리젠엑스바이오 인크. 완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
IL280198B2 (en) 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
KR20220131522A (ko) 2020-01-22 2022-09-28 리젠엑스바이오 인크. 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
WO2022170082A1 (en) 2021-02-05 2022-08-11 Regents Of The University Of Minnesota Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses

Similar Documents

Publication Publication Date Title
JP2020526514A5 (cg-RX-API-DMAC7.html)
JP2020537637A5 (cg-RX-API-DMAC7.html)
CN108310396B (zh) 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
ES2916344T3 (es) Composiciones y métodos para reducir la neovascularización ocular
JP7175506B2 (ja) 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ
IL273427B1 (en) Gene therapy for treating mucopolysaccharidosis type ii
US10098969B2 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
KR20160137908A (ko) 당뇨병-연관 심기능 장애 및 울혈성 심부전을 치료하기 위한 우로코르틴-2 및 연관 유전자들을 인코딩하는 바이러스 벡터들의 전신 전달
BR112021013876A2 (pt) Codificação de rhabdovírus recombinante para ccl21
JP2025506383A5 (cg-RX-API-DMAC7.html)
EP4433498A1 (en) Vectors for increasing nprl2 expression in cancer cells and methods of use thereof
JP2024531314A5 (cg-RX-API-DMAC7.html)
JP7413629B2 (ja) Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
JP2022530359A5 (cg-RX-API-DMAC7.html)
EP3570896B1 (en) Compositions for reducing sarcolipin expression and preventing and treating muscular dystrophy and cardiomyopathy and methods of use
JP2022523038A (ja) 遺伝子置換及び抗炎症を介したデュシェンヌ型筋ジストロフィーに対する一段階遺伝子療法
US20220088223A1 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
WO2020097150A1 (en) Treatment of traumatic brain injury
CA2978917C (en) Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
TW202503064A (zh) 用編碼阿柏西普之ａａｖ２變異體治療眼部新生血管性疾病之方法
Dagueta et al. Evolving knowledge in pharmacologic treatments of age-related macular degeneration
Transgene 290. A Rationally Engineered Novel Capsid Variant of AAV9 for Peripheral Tissue-Detargeted and CNS-Directed Systemic Gene Delivery